The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -21.66 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.03 — no flag raisedOK
- Earnings quality 83/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as SUTRO BIOPHARMA, INC. reports it. History and quarterly detail are in the app.
- Ongoing Performance Related To Unsatisfied Performance Obligations$50.4M
- Materials Supply$7.7M
- Financing Component On Unearned Revenue$3.4M
- Research And Development Services$2.5M
Leadership changes
From SUTRO BIOPHARMA, INC.'s own filings, the day they're filed.
- John Freund · member · departureeff. 2025-04-10
- Sukhi Jagpal · director · appointmenteff. 2024-08-08
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-06-08
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about SUTRO BIOPHARMA, INC., every answer cited to the official filings🔒
- The Intelligence Brief — added when SUTRO BIOPHARMA, INC.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.